CALR3

Summary

CALR3 (calreticulin 3, HGNC:20407) is a protein-coding gene on chromosome 19p13.11, encoding Calreticulin-3 (Q96L12). During spermatogenesis, may act as a lectin-independent chaperone for specific client proteins such as ADAM3.

The protein encoded by this gene belongs to the calreticulin family, members of which are calcium-binding chaperones localized mainly in the endoplasmic reticulum. This protein is also localized to the endoplasmic reticulum lumen, however, its capacity for calcium-binding may be absent or much lower than other family members. This gene is specifically expressed in the testis, and may be required for sperm fertility. Mutation in this gene has been associated with familial hypertrophic cardiomyopathy.

Source: NCBI Gene 125972 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hypertrophic cardiomyopathy (Disputed, ClinGen)
• GWAS associations: 3
• Clinical variants (ClinVar): 397 total
• Phenotypes (HPO): 2
• MANE Select transcript: NM_145046

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20407
Approved symbol	CALR3
Name	calreticulin 3
Location	19p13.11
Locus type	gene with protein product
Status	Approved
Aliases	CRT2, FLJ25355, MGC26577, CT93
Ensembl gene	ENSG00000269058
Ensembl biotype	protein_coding
OMIM	611414
Entrez	125972

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 3 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000269881, ENST00000600762, ENST00000602234, ENST00000932464

RefSeq mRNA: 1 — MANE Select: NM_145046 NM_145046

CCDS: CCDS12344

Canonical transcript exons

ENST00000269881 — 9 exons

Exon	Start	End
ENSE00000951611	16490367	16490570
ENSE00000951612	16485163	16485257
ENSE00000951613	16483930	16484115
ENSE00001049826	16479061	16479274
ENSE00001049827	16496039	16496167
ENSE00003467006	16495751	16495852
ENSE00003496903	16482678	16482785
ENSE00003539560	16480614	16480706
ENSE00003637161	16482450	16482581

Expression profiles

Bgee: expression breadth broad, 57 present calls, max score 94.47.

FANTOM5 (CAGE): breadth broad, TPM avg 0.5280 / max 89.3148, expressed in 249 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
179806	0.3199	171
179807	0.1373	30
179808	0.0709	11

Top tissues by expression

97 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	94.47	gold quality
left testis	UBERON:0004533	94.31	gold quality
testis	UBERON:0000473	93.98	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.25	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	47.67	gold quality
islet of Langerhans	UBERON:0000006	44.92	gold quality
hindlimb stylopod muscle	UBERON:0004252	41.98	gold quality
right coronary artery	UBERON:0001625	40.11	silver quality
adrenal tissue	UBERON:0018303	39.62	gold quality
pancreas	UBERON:0001264	38.97	gold quality
granulocyte	CL:0000094	38.56	gold quality
right uterine tube	UBERON:0001302	38.43	silver quality
liver	UBERON:0002107	37.96	silver quality
colonic epithelium	UBERON:0000397	37.20	gold quality
metanephros cortex	UBERON:0010533	36.74	silver quality
right adrenal gland cortex	UBERON:0035827	36.73	silver quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
fallopian tube	UBERON:0003889	35.82	gold quality
mucosa of transverse colon	UBERON:0004991	35.63	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
skeletal muscle tissue	UBERON:0001134	35.09	gold quality
right lung	UBERON:0002167	34.05	gold quality
ectocervix	UBERON:0012249	33.85	silver quality
right adrenal gland	UBERON:0001233	33.65	silver quality
muscle tissue	UBERON:0002385	33.51	gold quality
kidney	UBERON:0002113	33.47	gold quality
muscle of leg	UBERON:0001383	33.43	gold quality
adult mammalian kidney	UBERON:0000082	33.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.80

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 4)

• CRT2 is a novel cancer-testis antigen frequently expressed in various cancers (PMID:17975137)
• Calreticulin-2 is localized in the lumen of the endoplasmic reticulum but is not a Ca2+ -binding protein. (PMID:21590275)
• ADAM2, CALR3 and SAGE1 cancer/testis antigens are not promising targets for immunotherapy of breast and lung cancer. (PMID:26252478)
• CALR3 variant is not associated with cardiomyopathy in Dutch cohort. In three families, CALR3 mutation did not segregate with cardiomyopathy. (PMID:29988065)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Calr3	ENSMUSG00000019732
rattus_norvegicus	Calr3	ENSRNOG00000013260
caenorhabditis_elegans		WBGENE00000802

Paralogs (3): CANX (ENSG00000127022), CLGN (ENSG00000153132), CALR (ENSG00000179218)

Protein

Protein identifiers

Calreticulin-3 — Q96L12 (reviewed: Q96L12)

Alternative names: Calreticulin-2, Calsperin

All UniProt accessions (3): Q96L12, A0A140VJF7, M0R0Y8

UniProt curated annotations — full annotation on UniProt →

Function. During spermatogenesis, may act as a lectin-independent chaperone for specific client proteins such as ADAM3. Required for sperm fertility. CALR3 capacity for calcium-binding may be absent or much lower than that of CALR.

Subunit / interactions. Component of an EIF2 complex at least composed of CELF1/CUGBP1, CALR, CALR3, EIF2S1, EIF2S2, HSP90B1 and HSPA5.

Subcellular location. Endoplasmic reticulum lumen.

Tissue specificity. Testis specific.

Domain organisation. Can be divided into a N-terminal globular domain, a proline-rich P-domain forming an elongated arm-like structure and a C-terminal acidic domain. The P-domain binds one molecule of calcium with high affinity, whereas the acidic C-domain binds multiple calcium ions with low affinity. The interaction with glycans occurs through a binding site in the globular lectin domain. The zinc binding sites are localized to the N-domain.

Similarity. Belongs to the calreticulin family.

RefSeq proteins (1): NP_659483* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001580	Calret/calnex	Family
IPR009033	Calreticulin/calnexin_P_dom_sf	Homologous_superfamily
IPR009169	Calreticulin	Family
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR018124	Calret/calnex_CS	Conserved_site

Pfam: PF00262

UniProt features (28 total): repeat 7, region of interest 5, binding site 5, sequence variant 5, glycosylation site 2, signal peptide 1, chain 1, short sequence motif 1, disulfide bond 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96L12-F1	77.43	0.60

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5): 109; 111; 128; 135; 303

Disulfide bonds (1): 105–137

Glycosylation sites (2): 42, 201

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 65 (showing top): RRAGTTGT_UNKNOWN, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_ENDOPLASMIC_RETICULUM_STRESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_MALE_GAMETE_GENERATION, AACWWCAANK_UNKNOWN, GOBP_PROTEIN_MATURATION, GOBP_PROTEIN_FOLDING, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_ERAD_PATHWAY, GOBP_PROTEIN_CATABOLIC_PROCESS, ACTWSNACTNY_UNKNOWN, GOCC_NUCLEAR_ENVELOPE, GOCC_ENDOPLASMIC_RETICULUM_LUMEN

GO Biological Process (4): protein folding (GO:0006457), spermatogenesis (GO:0007283), cell differentiation (GO:0030154), ERAD pathway (GO:0036503)

GO Molecular Function (6): carbohydrate binding (GO:0030246), protein folding chaperone (GO:0044183), metal ion binding (GO:0046872), obsolete unfolded protein binding (GO:0051082), calcium ion binding (GO:0005509), protein binding (GO:0005515)

GO Cellular Component (4): nuclear envelope (GO:0005635), endoplasmic reticulum lumen (GO:0005788), endoplasmic reticulum membrane (GO:0005789), endoplasmic reticulum (GO:0005783)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
endomembrane system	2
cellular process	1
protein maturation	1
developmental process involved in reproduction	1
male gamete generation	1
cellular developmental process	1
proteasomal protein catabolic process	1
response to endoplasmic reticulum stress	1
response to chemical	1
molecular_function	1
protein folding	1
cation binding	1
metal ion binding	1
nucleus	1
organelle envelope	1
endoplasmic reticulum	1
intracellular organelle lumen	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cytoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1960 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CALR3	PDILT	Q8N807	697
CALR3	HSPA5	P11021	651
CALR3	HSP90B1	P14625	651
CALR3	JPH2	Q9BR39	620
CALR3	CASQ2	O14958	617
CALR3	RYR2	Q92736	617
CALR3	MYOZ2	Q9NPC6	596
CALR3	PRSS37	A4D1T9	595
CALR3	ADAM2	P78326	583
CALR3	MYPN	Q86TC9	577
CALR3	MYLK2	Q9H1R3	561
CALR3	TCAP	O15273	545
CALR3	MYL3	P08590	537
CALR3	CSRP3	P50461	527
CALR3	RNASE10	Q5GAN6	520

IntAct

8 interactions, top by confidence:

A	B	Type	Score
FAM217B	NCK2	psi-mi:“MI:0914”(association)	0.530
CALR3	UBR5	psi-mi:“MI:0914”(association)	0.530
CALR3	iglC2	psi-mi:“MI:0915”(physical association)	0.370
CALR3	CLN5	psi-mi:“MI:0914”(association)	0.350
MAEA	MPO	psi-mi:“MI:0914”(association)	0.350
CALR3	BMP4	psi-mi:“MI:0914”(association)	0.350

BioGRID (200): CALR3 (Affinity Capture-MS), UBR5 (Affinity Capture-MS), FAT1 (Affinity Capture-MS), OS9 (Affinity Capture-MS), GPR98 (Affinity Capture-MS), ITGA8 (Affinity Capture-MS), FREM2 (Affinity Capture-MS), CLN5 (Affinity Capture-MS), TMEM132A (Affinity Capture-MS), CALR3 (Affinity Capture-MS), UBR5 (Affinity Capture-MS), GPR98 (Affinity Capture-MS), ITGA8 (Affinity Capture-MS), TMEM132A (Affinity Capture-MS), CLN5 (Affinity Capture-MS)

ESM2 similar proteins: A0A0D1C6P2, A8XA40, D4AVD4, E2RA18, J9VLH0, O04151, O04153, O14967, O60164, O81919, O82709, P08110, P14625, P24643, P27824, P27825, P29402, P29413, P34652, P35016, P35564, P35565, P36581, P41148, P52194, P83003, P93508, Q06814, Q10651, Q12797, Q23858, Q29092, Q2TBR8, Q38798, Q38858, Q39817, Q39994, Q3SYT6, Q40401, Q4R520

Diamond homologs: A0A0D1C6P2, A8XA40, D4AVD4, E2RA18, J9VLH0, O04151, O04153, O14967, O81919, O82709, P11012, P14211, P15253, P18418, P24643, P27797, P27798, P27824, P27825, P28491, P29402, P29413, P34652, P35564, P35565, P36581, P52193, P52194, P83003, P93508, Q06814, Q23858, Q2HWU3, Q2TBR8, Q38798, Q38858, Q39817, Q39994, Q3SYT6, Q40401

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

397 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	220
Likely benign	112
Benign	48

Top pathogenic / likely-pathogenic (0)

SpliceAI

1140 predictions. Top by Δscore:

Variant	Effect	Δscore
19:16479271:GACC:G	acceptor_gain	1.0000
19:16479272:ACC:A	acceptor_gain	1.0000
19:16479273:CC:C	acceptor_gain	1.0000
19:16479273:CCC:C	acceptor_gain	1.0000
19:16479274:CC:C	acceptor_gain	1.0000
19:16479275:C:CC	acceptor_gain	1.0000
19:16479275:C:T	acceptor_gain	1.0000
19:16479276:T:A	acceptor_loss	1.0000
19:16479276:T:G	acceptor_loss	1.0000
19:16480609:CATA:C	donor_loss	1.0000
19:16480610:ATAC:A	donor_loss	1.0000
19:16480611:TAC:T	donor_loss	1.0000
19:16480611:TACC:T	donor_loss	1.0000
19:16480613:C:G	donor_loss	1.0000
19:16480707:C:CA	acceptor_loss	1.0000
19:16480708:T:G	acceptor_loss	1.0000
19:16482447:GAC:G	donor_loss	1.0000
19:16482448:AC:A	donor_loss	1.0000
19:16482449:C:G	donor_loss	1.0000
19:16482503:A:AC	donor_gain	1.0000
19:16482504:C:CC	donor_gain	1.0000
19:16482577:CCATC:C	acceptor_gain	1.0000
19:16482578:CATC:C	acceptor_gain	1.0000
19:16482578:CATCC:C	acceptor_gain	1.0000
19:16482579:ATCC:A	acceptor_loss	1.0000
19:16482580:TC:T	acceptor_gain	1.0000
19:16482581:CC:C	acceptor_gain	1.0000
19:16482581:CCTG:C	acceptor_gain	1.0000
19:16482582:C:A	acceptor_loss	1.0000
19:16482582:C:CC	acceptor_gain	1.0000

AlphaMissense

2575 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:16480675:A:G	L317P	0.996
19:16484087:A:G	L174P	0.995
19:16485257:C:T	G133E	0.995
19:16495835:A:G	W37R	0.995
19:16495835:A:T	W37R	0.995
19:16484010:A:G	W200R	0.993
19:16484010:A:T	W200R	0.993
19:16490470:T:A	K98N	0.993
19:16490470:T:G	K98N	0.993
19:16490367:C:G	G133R	0.992
19:16490367:C:T	G133R	0.992
19:16490481:A:C	Y95D	0.992
19:16495833:C:A	W37C	0.992
19:16495833:C:G	W37C	0.992
19:16490492:A:G	L91P	0.991
19:16496049:A:C	F27L	0.991
19:16496049:A:T	F27L	0.991
19:16496051:A:G	F27L	0.991
19:16482466:C:T	G301D	0.990
19:16490368:A:C	F132L	0.990
19:16490368:A:T	F132L	0.990
19:16490370:A:G	F132L	0.990
19:16495751:C:G	G65R	0.990
19:16479266:T:A	E340D	0.989
19:16479266:T:G	E340D	0.989
19:16484096:A:G	L171P	0.989
19:16485257:C:A	G133V	0.989
19:16490450:C:G	C105S	0.989
19:16490451:A:T	C105S	0.989
19:16490489:A:T	V92D	0.989

dbSNP variants (sampled 300 via entrez): RS1000171286 (19:16497315 G>A,C), RS1000192594 (19:16494341 C>T), RS1000344246 (19:16491306 T>C), RS1000798338 (19:16492903 G>A), RS1000812603 (19:16486368 T>A), RS1000988584 (19:16479931 G>A), RS1001179146 (19:16481549 G>A), RS1001240391 (19:16480908 C>A), RS1001326821 (19:16479636 G>A), RS1001342466 (19:16487574 A>G), RS1001446268 (19:16493598 G>A,C), RS1001515587 (19:16480545 C>A,G,T), RS1002140504 (19:16496543 C>G,T), RS1002192561 (19:16492039 G>A), RS1002480998 (19:16478870 A>G)

Disease associations

OMIM: gene MIM:611414 | disease phenotypes: MIM:613875, MIM:192600

GenCC curated gene-disease

Disease	Classification	Inheritance
hypertrophic cardiomyopathy	Disputed Evidence	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
hypertrophic cardiomyopathy	Disputed	AD

Mondo (7): hypertrophic cardiomyopathy 19 (MONDO:0013476), hypertrophic cardiomyopathy (MONDO:0005045), dilated cardiomyopathy (MONDO:0005021), familial hypertrophic cardiomyopathy (MONDO:0024573), cardiomyopathy (MONDO:0004994), arrhythmogenic right ventricular cardiomyopathy (MONDO:0016587), restrictive cardiomyopathy (MONDO:0005201)

Orphanet (7): Rare hypertrophic cardiomyopathy (Orphanet:217569), Dilated cardiomyopathy (Orphanet:217604), Rare familial disorder with hypertrophic cardiomyopathy (Orphanet:99739), Rare cardiomyopathy (Orphanet:167848), Inherited arrhythmogenic cardiomyopathy (Orphanet:247), Restrictive cardiomyopathy (Orphanet:217632), NON RARE IN EUROPE: Familial isolated hypertrophic cardiomyopathy (Orphanet:155)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0001639	Hypertrophic cardiomyopathy
HP:0001644	Dilated cardiomyopathy

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001137_3	White blood cell count	3.000000e-12
GCST90002389_397	Lymphocyte percentage of white cells	7.000000e-14
GCST90002399_228	Neutrophil percentage of white cells	5.000000e-10

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes

MeSH disease descriptors (6)

Descriptor	Name	Tree numbers
D019571	Arrhythmogenic Right Ventricular Dysplasia	C14.240.400.145; C14.280.238.028; C14.280.400.145; C16.131.240.400.145
D009202	Cardiomyopathies	C14.280.238
D002311	Cardiomyopathy, Dilated	C14.280.195.160; C14.280.238.070; C16.320.488.750
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160
D024741	Cardiomyopathy, Hypertrophic, Familial	C14.280.238.100.500; C14.280.484.048.750.070.160.500; C16.320.160
D002313	Cardiomyopathy, Restrictive	C14.280.238.160

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

2 total (human), top 2 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression	1
Smoke	decreases expression	1

Clinical trials (associated diseases)

299 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00879060	PHASE4	COMPLETED	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
NCT01721967	PHASE4	COMPLETED	Ranolazine for the Treatment of Chest Pain in HCM Patients
NCT02948998	PHASE4	UNKNOWN	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
NCT03249272	PHASE4	TERMINATED	Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT04133532	PHASE4	COMPLETED	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT06401343	PHASE4	RECRUITING	Use of SGLT2i in noHCM With HFpEF
NCT07103655	PHASE4	NOT_YET_RECRUITING	The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
NCT07600177	PHASE4	RECRUITING	Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT00374465	PHASE4	UNKNOWN	Therapy With Verapamil or Carvedilol in Chronic Heart Failure
NCT01293903	PHASE4	COMPLETED	Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
NCT01557140	PHASE4	COMPLETED	A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
NCT01917149	PHASE4	COMPLETED	Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy
NCT02115581	PHASE4	COMPLETED	Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
NCT06236022	PHASE4	RECRUITING	The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
NCT00317967	PHASE3	COMPLETED	Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
NCT00698074	PHASE3	UNKNOWN	Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
NCT00821353	PHASE3	COMPLETED	Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
NCT02431221	PHASE3	WITHDRAWN	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure
NCT03470545	PHASE3	COMPLETED	Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT05174416	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05182658	PHASE3	ACTIVE_NOT_RECRUITING	Empagliflozin in Hypertrophic Cardiomyopathy
NCT05186818	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05767346	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT06116968	PHASE3	COMPLETED	An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
NCT06873828	PHASE3	NOT_YET_RECRUITING	Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
NCT07021976	PHASE3	RECRUITING	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07023341	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07202897	PHASE3	NOT_YET_RECRUITING	LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
NCT00333827	PHASE3	COMPLETED	Cell Therapy In Dilated Cardiomyopathy
NCT00505154	PHASE3	COMPLETED	Effect of Rosuvastatin on Left Ventricular Remodeling
NCT01223703	PHASE3	COMPLETED	PUFAs and Left Ventricular Function in Heart Failure
NCT01583114	PHASE3	TERMINATED	PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
NCT01914081	PHASE3	UNKNOWN	Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside
NCT02989181	PHASE3	UNKNOWN	Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea
NCT03439514	PHASE3	TERMINATED	A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
NCT05237323	PHASE3	COMPLETED	Micophenolate Mofetil Versus Azathioprine in Myocarditis
NCT05849766	PHASE3	COMPLETED	Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction
NCT06250257	PHASE3	RECRUITING	Bromocriptine in Dilated Cardiomyopathy Among Women of Reproductive Age
NCT00001631	PHASE2	COMPLETED	Study of Blood Flow in Heart Muscle
NCT00001894	PHASE2	COMPLETED	A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy